Cellectis to present clinical data at EHA congress
Gene-editing company Cellectis will present clinical data on its lasme-cel and eti-cel cancer therapies at the European Hematology Association (EHA) annual congress.
French biotechnology firm Cellectis, specializing in gene-editing technologies, is set to present clinical data for two of its cancer therapies, lasme-cel and eti-cel, at the upcoming European Hematology Association (EHA) annual congress. These presentations will focus on the company's advancements in its CAR-T cell therapy programs.
The presented data will detail findings related to the company's developed CAR-T cell therapies, designed to target and eliminate cancer cells. Lasme-cel is under investigation for chronic lymphocytic leukemia (CLL), while eti-cel is being evaluated for acute lymphoblastic leukemia (ALL).
This participation at the EHA congress provides a platform for Cellectis to share insights into the early-stage results and therapeutic potential of these cell-based treatments. The company has previously secured approval from the U.S. Food and Drug Administration (FDA) to proceed with clinical studies for these candidates.
Cellectis' work involves genetically engineered T-cells and is currently part of several ongoing clinical trials. The company has also previously announced intentions for a U.S. initial public offering. These types of targeted cellular therapies are generating significant interest in the oncology field for their potential to offer new treatment avenues for patients.